GENVEC GETS CONTRACT EXTENSION OF HIV VACCINE DEVELOPMENT WORK

GenVec (GNVC) has received a $10 million one-year contract extension of its HIV vaccine development work with the Vaccine Research Center, part of the NIH's National Institute of Allergy and Infectious Diseases. In a press release, the biopharmaceutical company said the Vaccine Research Center will use the company's technologies for vaccine development, including its production cell line, 293-ORF6, to design and test next-generation vaccines to optimize the body's immune response to HIV.

iWon (http://money.iwon.com/jsp/nw/nwdt_rt.jsp?cat=USMARKET&src=704&feed=dji§ion=news&news_id=dji-00067820050112&date=20050112&alias=/alias/money/cm/nw)